Mirum Pharmaceuticals - MIRM STOCK NEWS

Mirum Pharmaceuticals announced the grant of non-qualified stock options for 191,400 shares to 17 new employees as part of its 2020 Inducement Plan. The exercise price is set at $17.18, matching the closing price on June 10, 2021. The options will vest over four years, subject to continued service. Additionally, Mirum is advancing its pipeline in liver disease treatment with maralixibat, which has a PDUFA action date of September 29, 2021, and has acquired two gene therapy programs for pediatric liver diseases from Vivet Therapeutics.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) appointed Dr. Carol L. Brosgart as an independent director on its Board. Dr. Brosgart brings a wealth of experience in healthcare and public policy, previously holding senior roles in various biotechnology firms. Chris Peetz, CEO, welcomed her at a crucial time as the company prepares for the potential launch of maralixibat, an investigational drug for Alagille syndrome. The company is advancing its pipeline, including gene therapy programs for pediatric liver diseases, which could significantly impact patient care.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) presented clinical analyses of maralixibat for treating Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis type 2 (PFIC2). Data indicates maralixibat's potential as a transformative therapy, possibly reducing the need for invasive surgeries. Findings from long-term studies show improved transplant-free survival and significant benefits in pruritus, quality of life, and growth with maralixibat treatment. The drug is generally well-tolerated, with transient mild to moderate adverse events. Regulatory submissions for maralixibat are underway.

Mirum Pharmaceuticals (Nasdaq: MIRM) announced that data from maralixibat studies will be presented at the 6th Annual World Congress of Pediatric Gastroenterology from June 2-5, 2021. Notable findings include an oral presentation by Professor Richard Thompson on the association between serum bile acid control and liver survival in children with PFIC. A poster presentation on gastrointestinal tolerability will also occur. A symposium discussing treatments for pediatric cholestasis will be held on June 3. Maralixibat is under investigation for rare cholestatic liver diseases, with significant results in ongoing trials.

Mirum Pharmaceuticals (Nasdaq: MIRM) announced on May 10, 2021, that its Compensation Committee granted stock options to purchase 87,500 shares to 9 new employees under the 2020 Inducement Plan. The options have an exercise price of $17.72 per share and will vest over four years, contingent upon continued employment. Mirum is focused on developing therapies for liver diseases, with its lead candidate maralixibat undergoing NDA review by the FDA, due by September 29, 2021. The company has also acquired options for gene therapy programs for PFIC2 and PFIC3, enhancing its product pipeline.

Mirum Pharmaceuticals reported its Q1 2021 financial results, highlighting significant progress in launching maralixibat for Alagille syndrome and an upcoming PDUFA date of September 29, 2021. The company secured a $120 million licensing deal with CANbridge Pharmaceuticals and raised $65 million from Oberland Capital. However, operating expenses surged to $47.6 million, with a net loss of $50.5 million or $1.68 per share. Despite increased expenses, Mirum's cash reserves stand at $213.1 million, supporting various clinical programs.

Mirum Pharmaceuticals (Nasdaq: MIRM) announced it will report financial results for the quarter ending March 31, 2021, on May 6, 2021. A conference call will follow at 1:30 PM PT/4:30 PM ET for a business update. The company focuses on developing therapies for liver diseases, with its lead candidate maralixibat currently under priority review by the FDA for cholestatic pruritus in ALGS patients, and a PDUFA action date set for September 29, 2021. Additionally, Mirum has secured options to develop gene therapy programs for PFIC2 and PFIC3.

Mirum Pharmaceuticals has partnered with CANbridge Pharmaceuticals to license maralixibat for development and commercialization in Greater China. This investigational oral medication is aimed at treating Alagille syndrome, progressive familial intrahepatic cholestasis, and biliary atresia. Mirum will receive an $11 million upfront payment, R&D funding, and up to $109 million in milestone payments, alongside tiered royalties based on sales. FDA has accepted an NDA for maralixibat under priority review, and CANbridge will manage clinical sites in China to enhance study enrollment.

Mirum Pharmaceuticals (Nasdaq: MIRM) has received a Notice of Allowance from the USPTO for patent application No. 16/994,368, which covers treatment methods for Alagille syndrome using maralixibat. This patent is set to provide protection until 2040. Additionally, the FDA accepted Mirum's NDA for maralixibat for treating cholestatic pruritus in patients one year and older, with a PDUFA date of September 29, 2021. Maralixibat, a novel investigational drug, is also being studied for progressive familial intrahepatic cholestasis and biliary atresia, and has shown promising results in clinical trials.